STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 106 filers reported holding STOKE THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 1.44 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $26,863 | -75.9% | 6,818 | -35.1% | 0.00% | – |
Q2 2023 | $111,689 | +236.0% | 10,507 | +163.3% | 0.00% | – |
Q1 2023 | $33,245 | +3501.8% | 3,991 | +3891.0% | 0.00% | – |
Q4 2022 | $923 | -81.5% | 100 | -70.9% | 0.00% | – |
Q3 2022 | $5,000 | -37.5% | 344 | -40.2% | 0.00% | – |
Q2 2022 | $8,000 | -75.8% | 575 | -63.0% | 0.00% | – |
Q1 2022 | $33,000 | -82.9% | 1,555 | -80.7% | 0.00% | – |
Q4 2021 | $193,000 | -31.6% | 8,041 | -27.4% | 0.00% | – |
Q3 2021 | $282,000 | +66.9% | 11,075 | +120.2% | 0.00% | – |
Q2 2021 | $169,000 | -61.9% | 5,029 | -55.9% | 0.00% | – |
Q1 2021 | $444,000 | -10.7% | 11,416 | +42.2% | 0.00% | – |
Q4 2020 | $497,000 | +160.2% | 8,030 | +40.9% | 0.00% | – |
Q3 2020 | $191,000 | -22.0% | 5,700 | -44.5% | 0.00% | – |
Q2 2020 | $245,000 | -49.6% | 10,271 | -51.6% | 0.00% | – |
Q1 2020 | $486,000 | -4.7% | 21,210 | +17.6% | 0.00% | – |
Q4 2019 | $510,000 | +589.2% | 18,030 | +424.0% | 0.00% | – |
Q3 2019 | $74,000 | – | 3,441 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ATP Life Science Ventures, L.P. | 16,786,713 | $562,187,000 | 75.80% |
RTW INVESTMENTS, LP | 3,544,248 | $118,697,000 | 2.86% |
Cormorant Asset Management, LP | 1,537,807 | $51,501,000 | 1.98% |
Redmile Group, LLC | 2,549,506 | $85,383,000 | 1.57% |
Birchview Capital, LP | 40,000 | $1,340,000 | 0.45% |
HighVista Strategies LLC | 17,082 | $572,000 | 0.42% |
Perceptive Advisors | 671,978 | $22,505,000 | 0.33% |
GILDER GAGNON HOWE & CO LLC | 1,490,153 | $49,905,000 | 0.31% |
Artal Group S.A. | 270,750 | $9,067,000 | 0.22% |
VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 323 | $11,000 | 0.20% |